piperidines has been researched along with Still-s-Disease--Adult-Onset* in 3 studies
3 other study(ies) available for piperidines and Still-s-Disease--Adult-Onset
| Article | Year |
|---|---|
Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China.
Topics: Adolescent; Adult; Aged; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Retreatment; Still's Disease, Adult-Onset | 2020 |
Tofacitinib-induced remission in refractory adult-onset Still's disease complicated by macrophage activation syndrome.
Topics: Aged; Fatal Outcome; Female; Humans; Janus Kinases; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Remission Induction; Still's Disease, Adult-Onset | 2020 |
[Successful treatment of adult Still's disease with tofacitinib in a HIV-2 positive female patient].
A 46-year-old female patient with a known HIV-2-infection suffered from adult onset Still's disease, which was initially complicated by a macrophage activation syndrome (MAS). The required glucocorticoid treatment induced a psychosis and the patient developed an aversion to glucocorticoids. After failure of treatment with anakinra, an alternative option with the JAK-inhibitor tofacitinib was introduced because of the short half-life and to reduce glucocorticoid exposure. A switch to tofacitinib was only successful after an overlapping treatment with anakinra and tofacitinib for 3 weeks. The patient is currently being treated with monotherapy with tofacitinib as well as NSAID on demand, is in stable remission and can continue working as normal. Topics: Adult; Female; HIV Infections; HIV-2; Humans; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Still's Disease, Adult-Onset; Treatment Outcome | 2020 |